TICKERNERD
Menu
CLOVCLOVHealthcare · Healthcare Plans

CLOV Stock Forecast: Clover Health Investments Corp. Price Predictions for 2026-2027

Last close, 18 Sept 2026
$4.46
−1.76% on the day

The 4 Wall Street analysts covering Clover Health Investments Corp. hold a median 12-month price target of $5.25 — +17.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 67 of 100 as at 19 Sept 2026 — in the upper half.

Market cap
$2.4B
Ticker Nerd rank
67 / 100
Median analyst target
$5.25
Analysts covering
4
Revenue$743.2M+55.6% y/y
Operating income$28.0M
Net income$28.0M
Free cash flow$24.5M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−7.5%
1M
+5.4%
YTD
+89.8%
1Y
+45.3%
From 52W high
−17.6%
From 52W low
+162.4%
$1.70
$5.41
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

CLOV stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Clover Health Investments Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 19 Sept 2026
67 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Revisions
85
Momentum
79
Growth
67
Accruals
63
Issuance
57
Quality
44
Value
42
Size
34
Volatility
21

Revisions (85): Analysts have, on balance, been raising their forecasts.

Volatility (21): The share price moves around a lot.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

CLOV stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on CLOV, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$1.00$2.00$3.00$4.00$5.00$6.00Oct 25Jan 26Apr 26Jul 26CLOVHigh $6.00Median $5.25Low $5.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says4 analysts
2 Buy2 Hold0 Sell
Low $5.00Median $5.25High $6.00

The green dot is the last close — the median target sits +17.7% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 4 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
6 Aug 2026UBSMaintainsNeutral$4.75 → $5.00
21 July 2026Canaccord GenuityMaintainsBuy$4.20 → $5.50
21 July 2026Canaccord GenuityMaintainsBuy—
11 June 2026UBSMaintainsNeutral$2.75 → $4.75
11 June 2026UBSMaintainsNeutral—
4 June 2026Canaccord GenuityMaintainsBuy$3.20 → $4.20
4 June 2026Canaccord GenuityMaintainsBuy—
20 Mar 2026Canaccord GenuityMaintainsBuy—
5 Mar 2026Leerink PartnersMaintainsMarket Perform—
20 Jan 2026Canaccord GenuityMaintainsBuy—
6 Nov 2025Canaccord GenuityMaintainsBuy—
7 Aug 2025Canaccord GenuityMaintainsBuy—
6 Aug 2025UBSMaintainsNeutral—
3 Mar 2025Canaccord GenuityMaintainsBuy—
17 Dec 2024Craig-HallumInitiatesBuy—
7 Oct 2024UBSInitiatesNeutral—
11 Aug 2023CitigroupMaintainsNeutral—
6 Mar 2023Canaccord GenuityMaintainsBuy—
6 Mar 2023Credit SuisseMaintainsUnderperform—
16 Nov 2022CitigroupMaintainsNeutral—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. CLOV appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

CLOV vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 18 Sept 2026, Clover Health Investments Corp. returned +45.3% against +16.3% for the S&P 500, dividends included.

CLOV vs S&P 500, last 12 monthsTotal return, rebased to 100
406080100120140160180Oct 25Jan 26Apr 26Jul 26CLOVS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

CLOV analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
+10.7%
Analysts raising
0
Analysts cutting
1
Fundamentals

Clover Health Investments Corp. (CLOV) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−26.2×

Cheaper than 97% of US stocks

Price / sales
1.0×

Cheaper than 70% of US stocks

Price / book
6.3×

Cheaper than 16% of US stocks

EV / EBITDA
−118.4×

Cheaper than 97% of US stocks

Growth & margins
Revenue growth (YoY)
55.6%

Higher than 88% of US stocks

Earnings growth (YoY)
55.6%

Higher than 76% of US stocks

Gross margin
20.6%

Higher than 22% of US stocks

Operating margin
3.8%

Higher than 52% of US stocks

Net margin
−0.7%

Higher than 29% of US stocks

Returns & dividend
Return on equity
−5.1%

Higher than 39% of US stocks

Return on assets
−1.8%

Higher than 38% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Clover Health Investments Corp. (CLOV) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Clover Health Investments Corp. has a market value of $2.4B and an enterprise value of $2.1B.

  • Revenue in the twelve months to 30 June 2026: $2.5B. The latest quarter grew 55.6% year on year.

  • Net income over the same four quarters: −$18.4M, a −0.7% net margin.

  • Diluted earnings per share, trailing twelve months: $−0.05.

  • Free cash flow in the twelve months to 30 June 2026: $74.2M.

  • Clover Health Investments Corp. spent $24.5M on share buybacks in the twelve months to 30 June 2026.

  • Shares outstanding: 529.1M.

  • Trailing P/E: −26.2×; forward P/E: 29.7× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Clover Health Investments Corp. employs 724 people — $3.4M of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 20 Sept 2026

Data provided by Twelve Data

Peers

CLOV vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelHealthcare Plans
CompanyMarket capTKN rank
CLOVClover Health Investments Corp.$2.4B
67
PGNYProgyny, Inc.$2.1B
96
ALHCAlignment Healthcare, Inc.$1.7B
62
OSCROscar Health, Inc.$9.6B
87
MOHMolina Healthcare, Inc.$10.3B
35
CNCCentene Corp.$32.0B
95
HUMHumana, Inc.$46.5B
43

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Clover Health Investments Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest CLOV news & analysis

Clover Health Sees PPO Edge, Cohort Gains as Medicare Advantage Pricing Tightens

MarketBeat · 18 Sept 2026positive

At Jefferies' Healthcare Services and Technology Conference in Nashville, Clover Health Investments' Interim Chief Financial Officer Clay Thornton said the company is positioning its Medicare Advantage business to benefit from industry pricing discipline, member retention, and the maturation of member cohorts.

Why it matters — A CLOV watcher would care because leadership is highlighting operational strengths in member retention and cohort maturation as Medicare Advantage pricing tightens across the industry.

Clover Health to Participate in Upcoming Investor Conferences

GlobeNewsWire · 31 Aug 2026neutral

Clover Health Investments announced that Interim Chief Financial Officer Clay Thornton will present at the 2026 Jefferies Healthcare Services and Technology Conference on September 15, 2026, at 1:40 p.m. The announcement was made via press release on August 31, 2026.

Why it matters — The company's participation in investor conferences gives analysts and shareholders a scheduled opportunity to hear directly from Clover Health's interim CFO about the business.

Clover Health Is A 'Buy' Because Of Its AI

Seeking Alpha · 26 Aug 2026positive

Seeking Alpha published a bullish analysis of Clover Health, citing its AI-powered Clover Assistant as a driver of lower claims costs and improved member profitability. The piece presents baseline and bullish DCF valuations and highlights membership growth, AI-enabled savings, and a potential Medicare Advantage bonus tied to a 4.5-star CMS rating.

Why it matters — The analysis frames Clover's AI capabilities and growth levers, including a potential CMS quality bonus, as key factors for investors monitoring the company's trajectory.

Clover Health Investments: Real Turnaround, But Already Priced In

Seeking Alpha · 15 Aug 2026neutral

Seeking Alpha rates Clover Health Investments (CLOV) a Hold, citing improved operational execution — Medicare Advantage membership grew 48% year over year and revenue and GAAP net income improved — but with a cautious outlook due to valuation and litigation risks. The firm notes profitability per member lags FY2024 levels, FY2026 guidance implies negative second-half results, and $120 million in quality bonus revenue is at risk pending a CMS litigation outcome.

Why it matters — For CLOV watchers, this item highlights that while the company's operational turnaround is real, the stock may already reflect that progress, leaving valuation and a potential CMS litigation outcome as key risks to the outlook.

Clover Health Is Proving Its Profit Model

Seeking Alpha · 14 Aug 2026positive

Clover Health reported strong growth and profitability, with improved guidance. Medicare Advantage membership grew 48% year-over-year, revenue rose 56%, and gross profit increased 54%, driven by cohort maturation and the Clover Assistant platform.

Why it matters — A CLOV watcher would care because Clover Health continues to post double-digit growth across membership, revenue, and gross profit while raising its guidance, signaling the durability of its profit model.

FAQ

Frequently asked questions about CLOV stock

What is the CLOV stock price forecast for 2026-2027?

The 4 Wall Street analysts covering Clover Health Investments Corp. have a median 12-month price target of $5.25, with estimates ranging from $5 to $6. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is CLOV stock a buy right now?

Of the 4 analysts covering Clover Health Investments Corp., 2 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Clover Health Investments Corp. 67 out of 100 across roughly 4,600 US stocks as at 19 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank CLOV?

As at 19 Sept 2026, Clover Health Investments Corp. ranks 67 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Revisions (85 of 100).

Will CLOV stock go up?

No one can know that. What the data says: the median 12-month target from 4 analysts implies +17.7% from the last close, and Ticker Nerd's factor model ranks Clover Health Investments Corp. 67 out of 100 as at 19 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the CLOV stock forecast for 2030?

No analyst covering Clover Health Investments Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CLOV are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $5 to $6 over the next 12 months.

How has CLOV stock performed over the past year?

Clover Health Investments Corp. returned +45.3% over the 12 months to 18 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Clover Health Investments Corp. do?

Clover Health Investments, Corp. Class A Common Stock represents an equity interest in Clover Health Investments, Corp., a healthcare company focused on Medicare Advantage plans in the United States.

What is the latest news on CLOV?

The most recent item we track (MarketBeat, 18 Sept 2026): "Clover Health Sees PPO Edge, Cohort Gains as Medicare Advantage Pricing Tightens". At Jefferies' Healthcare Services and Technology Conference in Nashville, Clover Health Investments' Interim Chief Financial Officer Clay Thornton said the company is positioning its Medicare Advantage business to benefit from industry pricing discipline, member retention, and the maturation of member cohorts.

Company

About Clover Health Investments Corp.

Clover Health Investments, Corp. Class A Common Stock represents an equity interest in Clover Health Investments, Corp., a healthcare company focused on Medicare Advantage plans in the United States. The company serves Medicare-eligible individuals through preferred provider organization and health maintenance organization plans, with a strong emphasis on broad-network coverage and coordinated care. Clover Health also operates Clover Assistant, a proprietary software platform that supports physicians by aggregating patient data and helping identify and manage chronic conditions earlier. Its business is centered on the insurance segment, combining managed care offerings with technology-enabled clinical support for medical providers. Based in Wilmington, Delaware, Clover Health occupies a niche in the healthcare market where insurance delivery and data-driven care management intersect.

CEO Mr. Andrew Toy · 724 employees · United States · https://www.cloverhealth.com